The Company’s existing financial guidance remains unchanged, with the acquisition supporting OXB’s long-term top-line growth outlook and existing near and medium-term financial guidance. The Company expects to deliver above-market growth, achieve EBITDA profitability from FY 2025, and strengthen its competitive position in the global viral vector market.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXBDF:
- Oxford BioMedica Expands US Operations with Key Acquisition
- Oxford Biomedica price target raised to 970 GBp from 930 GBp at RBC Capital
- Oxford Biomedica Reports Strong Revenue Growth in 2025
- Oxford BioMedica Reports Robust H1 2025 Results, Strengthens Market Position
- Oxford Biomedica Announces Total Voting Rights Update